The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection

被引：38

作者：

Maeda, K

Nakata, H

Ogata, H

Koh, Y

Miyakawa, T

Mitsuya, H ^{[1
]}

机构：

[1] Kumamoto Univ, Sch Med, Dept Infect Dis, Kumamoto 8608556, Japan

[2] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 8608556, Japan

[3] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA

来源：

CURRENT OPINION IN PHARMACOLOGY | 2004年 / 4卷 / 05期

关键词：

D O I：

10.1016/j.coph.2004.07.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The discovery of CCR5 as a HIV-1 co-receptor unfolded the cryptic and complicated process of HIV-1 cellular entry and has provided more than a few entry steps as possible modalities for effective viral intervention. The proof-of-principle has already been established for the use of entry inhibitors against HIV-1 and there is a cautious optimism that several CCR5 inhibitors might soon be added to our armamentarium for therapy of HIV-1 infection.

引用

页码：447 / 452

页数：6

共 66 条

[61] CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 [J].

Trkola, A ;

Dragic, T ;

Arthos, J ;

Binley, JM ;

Olson, WC ;

Allaway, GP ;

ChengMayer, C ;

Robinson, J ;

Maddon, PJ ;

Moore, JP .

NATURE, 1996, 384 (6605) :184-187

[62] Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry [J].

Tsamis, F ;

Gavrilov, S ;

Kajumo, F ;

Seibert, C ;

Kuhmann, S ;

Ketas, T ;

Trkola, A ;

Palani, A ;

Clader, JW ;

Tagat, JR ;

McCombie, S ;

Baroudy, B ;

Moore, JP ;

Sakmar, TP ;

Dragic, T .

JOURNAL OF VIROLOGY, 2003, 77 (09) :5201-5208

[63] Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection [J].

Veazey, RS ;

Klasse, PJ ;

Ketas, TJ ;

Reeves, JD ;

Piatak, M ;

Kunstman, K ;

Kuhmann, SE ;

Marx, PA ;

Lifson, JD ;

Dufour, J ;

Mefford, M ;

Pandrea, I ;

Wolinsky, SM ;

Doms, RW ;

DeMartino, JA ;

Siciliano, SJ ;

Lyons, K ;

Springer, MS ;

Moore, JP .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (10) :1551-1562

[64] Combinatorial synthesis of CCR5 antagonists [J].

Willoughby, CA ;

Berk, SC ;

Rosauer, KG ;

Degrado, S ;

Chapman, KT ;

Gould, SL ;

Springer, MS ;

Malkowitz, L ;

Schleif, WA ;

Hazuda, D ;

Miller, M ;

Kessler, J ;

Danzeisen, R ;

Holmes, K ;

Lineberger, J ;

Carella, A ;

Carver, G ;

Emini, EA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (24) :3137-3141

[65] Frequency of the HIV-protective CC chemokine receptor 5-Δ32/Δ32 genotype is increased in hepatitis C [J].

Woitas, RP ;

Ahlenstiel, G ;

Iwan, A ;

Rockstroh, JK ;

Brackmann, HH ;

Kupfer, B ;

Matz, B ;

Offergeld, R ;

Sauerbruch, T ;

Spengler, U .

GASTROENTEROLOGY, 2002, 122 (07) :1721-1728

[66] CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 [J].

Wu, LJ ;

Gerard, NP ;

Wyatt, R ;

Choe, H ;

Parolin, C ;

Ruffing, N ;

Borsetti, A ;

Cardoso, AA ;

Desjardin, E ;

Newman, W ;

Gerard, C ;

Sodroski, J .

NATURE, 1996, 384 (6605) :179-183

← 1 2 3 4 5 6 7 →